Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
A total of 14 investors have a majority stake in the company with 50% ownership Institutional ownership in Immunome is 30% A look at the shareholders of Immunome, Inc. ( NASDAQ:IMNM ) can tell us which group is most powerful. With 42% stake, individual investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company. While individual investors were the group that benefitted the most from last week's US$95m market cap gain, institutions too had a 30% share in those profits. Let's delve deeper into each type of owner of Immunome, beginning with the chart below. Check out our latest analysis for Immunome What Does The Institutional Ownership Tell Us About Immunome? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Immunome does have
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for [Yahoo! Finance]Yahoo! Finance
- Immunome Appoints Sandra M. Swain to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Immunome Appoints Sandra M. Swain to Board of DirectorsBusiness Wire
- Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling [Seeking Alpha]Seeking Alpha
IMNM
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- IMNM's page on the SEC website